Clinical effect of Biejia Ruangan Tablets combined with Entecavir in the treatment of chronic hepatitis B
SUN Xiu-guang1 XU Juan2 PAN Jin-ping1
1. Department of Hepatology, People′s Hospital of Yichun City, Jiangxi Province, Yichun 336000, China;
2. Rehab Branch, People′s Hospital of Yichun City, Jiangxi Province, Yichun 336000, China
Abstract：Objective To investigate the clinical effect of Biejia Ruangan Tablets (BRT) combined with Entecavir (ETV)in the treatment of chronic hepatitis B (CHB). Methods A total of 174 CHB patients treated in People′s Hospital of Yichun City from September 2016 to December 2018 were selected as the research objects and divided into the control group and the observation group by random number table method, with 87 cases in each group. The control group was treated with ETV, and the observation group was treated with ETV and BRT. Liver inflammation grade, liver fibrosis grade, HBV DNA copy amount, serum alanine aminotransferase (ALT) and liver fibrosis index (hyaluronic acid [HA],type Ⅲprocollagen [PCⅢ], type Ⅳcollagen [Ⅳ-C], laminin [LN]) levels in the two groups were compared. Results At the 48th week of treatment, the grade of liver inflammation in the two groups were better than those before treatment,and the differences were statistically significant (P＜0.05). At the 48th week of treatment, there was no statistically significant difference in the grade of liver inflammation between the two groups (P＞0.05). At the 48th week of treatment,the grade of liver fibrosis in the observation group was better than that in the control group, and the difference was statistically significant (P＜0.05). Before treatment, there were no statistically significant differences in serum ALT, HA, PCⅢ, Ⅳ-C and LN levels between the two groups (P＞0.05). At the 48th week of treatment, the levels of ALT, HA, PCⅢ,Ⅳ-C and LN in the two groups were lower than those before treatment, and the differences were statistically significant(P＜0.05). At the 48th week of treatment, the levels of ALT, HA, PCⅢ, Ⅳ-C and LN in the observation group were lower than those in the control group, and the differences were statistically significant (P＜0.05). There were no statistically significant differences in HBV DNA copy between the two groups before treatment, at the 12th, 24th and 48th week of treatment (P＞0.05). Conclusion BRT is an effective adjuvant therapy for CHB, and it is of great value in improving the process of liver fibrosis.
孙秀光；徐娟；潘金平. 鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎的临床效果[J]. 中国当代医药, 2021, 28(28): 13-16-20.
SUN Xiu-guang；XU Juan；PAN Jin-ping. Clinical effect of Biejia Ruangan Tablets combined with Entecavir in the treatment of chronic hepatitis B. 中国当代医药, 2021, 28(28): 13-16-20.
Tamaki N，Kurosaki M，Kirino S，et al.Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir[J].JGH Open，2019，4（3）：429-432.
[2]
Menne S，Wildum S，Steiner G，et al.Efficacy of an Inhibitor of Hepatitis B Virus Expression in Combination With Entecavir and Interferon-α in Woodchucks Chronically Infected With Woodchuck Hepatitis Virus[J].Hepatol Commun，2020，4（6）：916-931.
[3]
Huang C，Shen D，Sun S，et al.Effect of Fufang Biejia Ruangan Tablet on lowering biochemical and virological parameters of hepatic fibrosis in patients with chronic hepatitis B：Protocol for a systematic review and meta-analysis of randomized controlled trials and cohort studies[J].Medicine（Baltimore），2019，98（17）：e15297.
Chen CJ，Yu HC，Chang CW，et al.Efficacy of telbivudine and entecavir against virus reactivation in HBeAg-patients undergoing chemotherapy[J].Medicine（Baltimore），2020，99（22）：e20330.
Wang HW，Lai HC，Hu TH，et al.On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma[J].Cancers（Basel），2020，12（5）：1177.
[11]
Kamal F，Khan MA.Is Tenofovir Associated with a Lower Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Compared With Entecavir?[J].Gastroenterology，2020，158（8）：2311-2312.
[12]
Wani MA，Sodhi JS，Zargar SA，et al.Entecavir is Safe and Effective in Long Term for the Treatment of Hepatitis B in Immunocompromised Children[J].J Clin Exp Hepatol，2020，10（2）：150-154.
[16]
Zhou J，Chen XM，Liu SW，et al.Effects of Biejia Ruangan Tablet-containing serum on matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in cultured renal interstitial fibroblasts[J].Chin J Integr Med，2015，21（2）：152-156.
京公网安备 11010502046607号